Advanced Viral's AVR 118 study shows accelerated wound healing

By Elaine Rigoli

Tampa, Fla., Aug. 7 - Advanced Viral Research Corp. announced that a wound healing study topically applying its pharmaceutical drug AVR 118 to pigs has shown that AVR 118 accelerates the rate at which wounds heal.

Although preliminary, the company said these studies provide the rationale for advancing AVR 118 to the human testing stage.

"This study has already generated interest from two major dermatological and wound healing centers in North America and Europe and we intend to move forward with a clinical trial plan," president and chief executive officer Stephen M. Elliston said in a news release.

"These findings are extremely important because the regenerative properties of the pig model closely parallel those of humans. The wounds treated in this study with AVR 118 healed faster than those treated with a saline control," added Elliston.

Advanced Viral Research is a New York-based biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.